358 related articles for article (PubMed ID: 35432344)
1. Cancer Cell Phenotype Plasticity as a Driver of Immune Escape in Melanoma.
Benboubker V; Boivin F; Dalle S; Caramel J
Front Immunol; 2022; 13():873116. PubMed ID: 35432344
[TBL] [Abstract][Full Text] [Related]
2. ZEB1 transcription factor promotes immune escape in melanoma.
Plaschka M; Benboubker V; Grimont M; Berthet J; Tonon L; Lopez J; Le-Bouar M; Balme B; Tondeur G; de la Fouchardière A; Larue L; Puisieux A; Grinberg-Bleyer Y; Bendriss-Vermare N; Dubois B; Caux C; Dalle S; Caramel J
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35288462
[TBL] [Abstract][Full Text] [Related]
3. Epithelial-to-mesenchymal transition in cancer progression: unraveling the immunosuppressive module driving therapy resistance.
Singh D; Siddique HR
Cancer Metastasis Rev; 2024 Mar; 43(1):155-173. PubMed ID: 37775641
[TBL] [Abstract][Full Text] [Related]
4. Phenotype Switching and the Melanoma Microenvironment; Impact on Immunotherapy and Drug Resistance.
Hossain SM; Eccles MR
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36675114
[TBL] [Abstract][Full Text] [Related]
5. Phenotypic tumour cell plasticity as a resistance mechanism and therapeutic target in melanoma.
Roesch A; Paschen A; Landsberg J; Helfrich I; Becker JC; Schadendorf D
Eur J Cancer; 2016 May; 59():109-112. PubMed ID: 27023049
[TBL] [Abstract][Full Text] [Related]
6. Melanoma spheroids grown under neural crest cell conditions are highly plastic migratory/invasive tumor cells endowed with immunomodulator function.
Ramgolam K; Lauriol J; Lalou C; Lauden L; Michel L; de la Grange P; Khatib AM; Aoudjit F; Charron D; Alcaide-Loridan C; Al-Daccak R
PLoS One; 2011 Apr; 6(4):e18784. PubMed ID: 21526207
[TBL] [Abstract][Full Text] [Related]
7. EMT-induced immune evasion: connecting the dots from mechanisms to therapy.
Imodoye SO; Adedokun KA
Clin Exp Med; 2023 Dec; 23(8):4265-4287. PubMed ID: 37966552
[TBL] [Abstract][Full Text] [Related]
8. Immune escape and metastasis mechanisms in melanoma: breaking down the dichotomy.
Shirley CA; Chhabra G; Amiri D; Chang H; Ahmad N
Front Immunol; 2024; 15():1336023. PubMed ID: 38426087
[TBL] [Abstract][Full Text] [Related]
9. Wnt-signaling enhances neural crest migration of melanoma cells and induces an invasive phenotype.
Sinnberg T; Levesque MP; Krochmann J; Cheng PF; Ikenberg K; Meraz-Torres F; Niessner H; Garbe C; Busch C
Mol Cancer; 2018 Feb; 17(1):59. PubMed ID: 29454361
[TBL] [Abstract][Full Text] [Related]
10. How Neural Crest Transcription Factors Contribute to Melanoma Heterogeneity, Cellular Plasticity, and Treatment Resistance.
Wessely A; Steeb T; Berking C; Heppt MV
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34071193
[TBL] [Abstract][Full Text] [Related]
11. New insights into the role of EMT in tumor immune escape.
Terry S; Savagner P; Ortiz-Cuaran S; Mahjoubi L; Saintigny P; Thiery JP; Chouaib S
Mol Oncol; 2017 Jul; 11(7):824-846. PubMed ID: 28614624
[TBL] [Abstract][Full Text] [Related]
12. Reprogramming metastatic melanoma cells to assume a neural crest cell-like phenotype in an embryonic microenvironment.
Kulesa PM; Kasemeier-Kulesa JC; Teddy JM; Margaryan NV; Seftor EA; Seftor RE; Hendrix MJ
Proc Natl Acad Sci U S A; 2006 Mar; 103(10):3752-7. PubMed ID: 16505384
[TBL] [Abstract][Full Text] [Related]
13. Tumor plasticity interferes with anti-tumor immunity.
Chouaib S; Janji B; Tittarelli A; Eggermont A; Thiery JP
Crit Rev Immunol; 2014; 34(2):91-102. PubMed ID: 24940910
[TBL] [Abstract][Full Text] [Related]
14. The mechanical phenotypic plasticity of melanoma cell: an emerging driver of therapy cross-resistance.
Diazzi S; Tartare-Deckert S; Deckert M
Oncogenesis; 2023 Feb; 12(1):7. PubMed ID: 36774337
[TBL] [Abstract][Full Text] [Related]
15. Tumor Immune Microenvironment during Epithelial-Mesenchymal Transition.
Taki M; Abiko K; Ukita M; Murakami R; Yamanoi K; Yamaguchi K; Hamanishi J; Baba T; Matsumura N; Mandai M
Clin Cancer Res; 2021 Sep; 27(17):4669-4679. PubMed ID: 33827891
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms of Immunotherapy Resistance in Cutaneous Melanoma: Recognizing a Shapeshifter.
Thornton J; Chhabra G; Singh CK; Guzmán-Pérez G; Shirley CA; Ahmad N
Front Oncol; 2022; 12():880876. PubMed ID: 35515106
[TBL] [Abstract][Full Text] [Related]
17. Dedifferentiated melanomas: Morpho-phenotypic profile, genetic reprogramming and clinical implications.
Massi D; Mihic-Probst D; Schadendorf D; Dummer R; Mandalà M
Cancer Treat Rev; 2020 Aug; 88():102060. PubMed ID: 32619863
[TBL] [Abstract][Full Text] [Related]
18. Communication between EMT and PD-L1 signaling: New insights into tumor immune evasion.
Jiang Y; Zhan H
Cancer Lett; 2020 Jan; 468():72-81. PubMed ID: 31605776
[TBL] [Abstract][Full Text] [Related]
19. Plasticity of melanoma cells induced by neural cell crest conditions and three-dimensional growth.
Ghislin S; Deshayes F; Lauriol J; Middendorp S; Martins I; Al-Daccak R; Alcaide-Loridan C
Melanoma Res; 2012 Jun; 22(3):184-94. PubMed ID: 22454190
[TBL] [Abstract][Full Text] [Related]
20. Epithelial-Mesenchymal Transition Signaling and Prostate Cancer Stem Cells: Emerging Biomarkers and Opportunities for Precision Therapeutics.
Chaves LP; Melo CM; Saggioro FP; Reis RBD; Squire JA
Genes (Basel); 2021 Nov; 12(12):. PubMed ID: 34946849
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
